May 22, 2025
Will econs drive a further pricing retreat, I’d wait on sector equities through Friday?
As there exists an attractive risk-reward opportunity to buy dips in Treasuries with yields pushing higher
Breaking: In the week ending May 17, the advance figure for seasonally adjusted initial claims was 227,000, a decrease of 2,000 from the previous week's unrevised level of 229,000. The 4-week moving average was 231,500, an increase of 1,000 from the previous week's unrevised average of 230,500.
A 3-day weekend ahead, can’t come soon enough!
No false narratives or fake news; to read insights and analysis on the latest sector action, check out Pre-Open Brief
Never leave an investor uninformed!
May 22, 2025
Newest ...
Harvard Apparatus RT (OTCQB: HRGN) Net loss of -$1.659 M or -$0.10 per share, revenue of $45 K, cash position of $1.728 M with a Q2/25 runway; accumulated deficit of -$101.3 M, liabilities of -$11.9 K in addition to -$207 K owed to former employees, and 161 K to Un of Pitt and Yale <No release, 8-K, filed 5/14>.
What about past consultants with documentation!! Going Concern status still in effect.
4/28/25: NO clinical data as trial falters with patient enrollment issues yet the salaries and bonuses of CEO and MNGT team are OUTSTANDING and for WHAT?
May 22, 2025
Sector equity year-to-date performance remains bottom-based
The wall of worry emerges as valuations are inflated then deflated while economic-related gradations are heightened, on and on
Expect volatility to be more the norm versus exception
Always be vigilant concerning your portfolio … why you need RMi!
Never leave an investor uninformed!
May 22, 2025
Newest ... Harvard Apparatus RT (OTCQB: HRGN) Net loss of -$1.659 M or -$0.10 per share, revenue of $45 K, cash position of $1.728 M with a Q2/25 runway; accumulated deficit of -$101.3 M, liabilities of -$11.9 K in addition to -$207 K owed to former employees, and 161 K to Un of Pitt and Yale <No release, 8-K, filed 5/14>. What about past consultants with documentation!! Going Concern status still in effect. 4/28/25: NO clinical data as trial falters with patient enrollment issues yet the salaries and bonuses of CEO and MNGT team are OUTSTANDING and for WHAT? Is Beijing, China coming to the rescue again, NOT if President Trump has a say! I have another question after many, how maany U.S.citizens work at HRGN versus green-carded with a couple canadian passports
May 13, 2025
SGMO is trading at $0.449 down -$0.2967 or -39.7% Cantor is acting as sole book-running manager for the offering.
March 10, 2025
including pre-funded warrants to purchase 1,404,988 shares of common stock at an offering price of $28.47 per pre-funded warrant with an exercise price of $0.01 per share. BEAM closed Friday at $1.23 to $28.48 with a pre-open indication of $2.57 or +0.02% to $31.05 Gross proceeds from the offering are expected to be approximately $500.0 million expected to close on or about 3/11/2525
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
